Review anchor
Sodium channel protein type 4 subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Sodium channel protein type 4 subunit alpha
CHEMBL2072
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel protein type 4 subunit alpha as ChEMBL target CHEMBL2072, mapped to UniProt P35499. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2072
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P35499
Sodium channel protein type 4 subunit alpha
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sodium channel protein type 4 subunit alpha matters
Sodium channel protein type 4 subunit alpha is reviewed as Sodium channel protein type 4 subunit alpha (UniProt P35499); Sodium channel protein type 4 subunit alpha shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 445 compounds, and 63 assays, with lead potency reaching pChEMBL 10.2.
Protein context
Sodium channel protein type 4 subunit alpha
Sodium channel protein type 4 subunit alpha Sequence length is 1836 aa.
Review this target as Sodium channel protein type 4 subunit alpha, mapped to UniProt P35499. Sequence length is 1836 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P35499
Protein
Disease context
pain
Sodium channel protein type 4 subunit alpha shows approved-linked disease relevance led by pain. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE, LEVOBUPIVACAINE HYDROCHLORIDE.
Start review with pain because it currently carries approved-linked support. Linked drugs include BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE, LEVOBUPIVACAINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
3 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 445 compounds, and 63 assays for this target. The dominant activity type is IC50. CHEMBL3617050 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL3617050 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 10.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sodium channel protein type 4 subunit alpha matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35499, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why pain is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
445
Total Compounds
63
Total Assays
5
Approved Drugs
IC50: 474.0, KI: 15.0, EC50: 44.0, KD: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3617050
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL501134
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL5189924
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL5192731
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL5094715
|
8.5 | IC50 | — |
Source Header